The objective of this study was to evaluate the determinants of long-term adherence to positive airway pressure treatment among patients with obstructive sleep apnea, with special emphasis on patients who stop positive airway pressure treatment within 1 year. This is a prospective long-term follow-up of subjects in the Icelandic Sleep Apnea Cohort who were diagnosed with obstructive sleep apnea between 2005 and 2009, and started on positive airway pressure treatment. In October 2014, positive airway pressure adherence was obtained by systematically evaluating available clinical files (n = 796; 644 males, 152 females) with moderate to severe obstructive sleep apnea (apnea-hypopnea index ≥15 events per h). The mean follow-up time was 6.7 AE 1.2 years. In total, 123 subjects (15.5%) returned their positive airway pressure device within the first year, 170 (21.4%) returned it later and 503 (63.2%) were still using positive airway pressure. The quitters within the first year had lower body mass index, milder obstructive sleep apnea, less sleepiness, and more often had symptoms of initial and late insomnia compared with long-term positive airway pressure users at baseline. Both initial and late insomnia were after adjustment still significantly associated with being an early quitter among subjects with body mass index <30 kg m À2 , but not among those with body mass index ≥30 kg m À2 . The prevalence of early quitters decreased significantly during the study period (2005)(2006)(2007)(2008)(2009). Almost two-thirds of patients with moderate to severe obstructive sleep apnea are positive airway pressure users after 7 years. Obesity level, obstructive sleep apnea severity and daytime sleepiness are important determinants of long-term adherence. Symptoms of initial and late insomnia are associated with early quitting on positive airway pressure among non-obese subjects.
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STATEMENT O F SI GN IFIC ANCE
This study is important as it evaluates the determinants of long-term adherence to positive airway pressure (PAP) treatment, and puts a special focus on subjects who stop treatment in the first year. Previous studies have indicated that PAP adherence is often poor, and therefore it is important to identify factors that negatively affect adherence and find ways to increase PAP use. Our results show that patients with a higher body mass index (BMI), more severe obstructive sleep apnea (OSA) and daytime sleepiness are likely to adhere to PAP treatment. Leaner subjects with symptoms of insomnia are on the other hand at risk of discontinuing PAP and may need additional treatment ª 2016 European Sleep Research Society interventions. Future studies should focus on interventions aimed at insomnia symptoms among patients with OSA with a lower BMI.
IN TROD UCTI ON
Obstructive sleep apnea (OSA) is a chronic disorder characterized by repeated episodes of partial or complete upper airway collapse during sleep (Bouloukaki et al., 2014; Punjabi, 2008; Weaver and Sawyer, 2010) . This can lead to excessive daytime sleepiness, impaired cognition, mood alterations, decreased functional capacity, and increased risk of cardiovascular disease (CVD) and motor vehicle crashes (Bouloukaki et al., 2014; Punjabi, 2008; Weaver and Sawyer, 2010) . Positive airway pressure (PAP) therapy has been established as the primary treatment for patients with moderate to severe OSA (Bouloukaki et al., 2014; Sawyer et al., 2011; Weaver and Sawyer, 2010) . The effectiveness of PAP treatment significantly depends on patient adherence to the therapy, and lack of PAP adherence is a well-recognized limitation of the effectiveness of OSA treatment (Bouloukaki et al., 2014; Jurado-Gamez et al., 2015; Sawyer et al., 2011; Weaver, 2006; Weaver and Grunnstein, 2008; Weaver and Sawyer, 2010; Wohlgemuth et al., 2015) . Patient adherence during the first month after initiation of PAP therapy is a powerful predictor of long-term adherence (DeMolles et al., 2014) , and the first week of PAP treatment can be critically influential on the patient decision to use PAP (Weaver et al., 1997) . Several studies have pointed out the need to identify patients who are at the greatest risk for quitting PAP treatment in order to be able to develop a more personalized approach to improve overall adherence (Rose, 2006; Sawyer et al., 2011 Sawyer et al., , 2014 .
A limited number of studies address long-term adherence to PAP (Bouloukaki et al., 2014; Galetke et al., 2011; Kohler et al., 2010; Salepci et al., 2013; Schoch et al., 2014; Zeller et al., 2013) , but available studies indicate that increased OSA severity is associated with greater PAP adherence (Bouloukaki et al., 2014; Galetke et al., 2011; Schoch et al., 2014) .
Obesity is an important risk factor for OSA and often associated with more severe OSA (Young et al., 2005) . However, studies by Galetke et al. (2011) and Kohler et al. (2010) did not find obesity to be associated with long-term PAP adherence. Furthermore, in a study by Schoch et al. (2014) , overweight patients [body mass index (BMI) between 27 and 30.5 kg m À2 ] were more likely to adhere to PAP than leaner patients and obese patients (BMI over 30.5 kg m À2 ).
Symptoms of insomnia have also been associated with worse PAP adherence. Our previous study (Bjornsdottir et al., 2012) indicated that symptoms of initial and late insomnia do not improve on PAP treatment, and these symptoms negatively affect PAP adherence. Others have reported similar results, especially showing patients who have difficulties falling asleep to have worse adherence to PAP treatment (Salepci et al., 2013) . There is, however, a lack of studies comparing simultaneously OSA severity, obesity, sleepiness and other symptoms related to OSA in those who quit PAP early and those who manage to use PAP for the long term. The aims of this study were therefore to review long-term PAP adherence in a well-defined cohort of patients with OSA and to identify groups that are at risk for stopping PAP treatment, with a special emphasis on those who quit treatment within the first year (early quitters). (Arnardottir et al., 2013a,b; Bjornsdottir et al., 2012 Bjornsdottir et al., , 2013 Bj€ ornsdottir et al., 2015) . No other inclusion or exclusion criteria were used. Over 90% of eligible and approached subjects agreed to participate in the prospective cohort at baseline and started PAP treatment.
MAT ERIALS AN D METH ODS
All PAP treatment in Iceland is administered by the Department of Respiratory Medicine and Sleep at LSH. All participants in the ISAC cohort study started treatment with an auto-adjusting PAP or continuous PAP device (ResMed, San Diego, California, USA), and were only changed to bilevel PAP or adaptive servo ventilation if treatment efficacy was inadequate, defined by AHI ≥15 events per h while using PAP and/or persistent patient complaints. As part of routine care, all patients with OSA paid a monthly usage fee (22 US$ per month) for their PAP device, had access to the outpatient clinic and were in a regularly updated registry. Various mask types and humidifiers were available for all patients on PAP. Since 2009 all PAP devices had heated in-line humidifiers.
The electronic medical files of all 822 patients in the ISAC study were reviewed in October 2014. A total of 22 patients had died and four patients were living abroad. The files of the 796 remaining patients were reviewed for their last sleep clinic visit and whether they had returned their PAP device. Long-term PAP users were defined as those still having a PAP device and paying the monthly user fee. Patients who had stopped their PAP treatment were divided into four groups ( Fig. 1 ): early PAP quitters (stopped using PAP within 1 year); those who stopped using PAP between 1 and 2 years (n = 62); after 2-4 years (n = 85); and after 5-7 years (n = 23); all these groups except the early quitters were later combined into late quitters as no differences were found between the groups in baseline characteristics (data not shown). The focus of the current study was to compare early PAP quitters and long-term PAP users.
The ISAC study was approved by the Iceland's National Bioethics Committee, the Data Protection Authority of Iceland and the Institutional Review Board of the University of Pennsylvania.
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Measurements and questionnaires
Before participants started PAP treatment, written informed consent was obtained and patients answered standardized questionnaires about their health and sleep. These questionnaires included questions about whether they had hypertension and/or diabetes (doctor diagnosis and medication), as well as CVD defined as a medical diagnosis of myocardial infarction or heart attack, heart failure and/or stroke. The Epworth Sleepiness Scale (ESS) was used to evaluate daytime sleepiness; participants with ESS score ≥10 were considered to have excessive daytime sleepiness (Johns, 1992) .
Sleep symptoms were assessed using the Basic Nordic Sleep Questionnaire, which includes questions on insomnia, nocturnal sweating, daytime sleepiness and sleep bruxism (Partinen and Gislason, 1995) . The response alternatives for those questions were on a frequency scale of 1-5: (1) never or very seldom; (2) less than once a week; (3) once-twice a week; (4) three-five times a week; and (5) every day or almost every day of the week. Those scoring 4 or 5 were defined as having the symptom (Partinen and Gislason, 1995) . Insomnia symptoms were defined into three subtypes; difficulty initiating sleep (initial insomnia); difficulty maintaining sleep (middle insomnia); and early morning awakenings (late insomnia); for more details see our previous publication (Bjornsdottir et al., 2013) . The Short Form Health Survey (SF-12) was used to assess quality of life. Both physical and mental health summary scores were derived from the SF-12. These scores range from 0 to 100, where a score of zero indicates the lowest life quality and 100 indicates the highest life quality (Ware et al., 1996) . Questions on symptoms of restless legs syndrome (RLS) were based on recommendations from the International Restless Legs Syndrome Study Groups (Allen et al., 2003) .
Sleep recording in ISAC cohort
Prior to referral for PAP treatment, all patients with OSA had a type 3 sleep study performed with eitheran Embletta portable monitor, an Embla 12 channel system (Natus Medical, Oakville, ON, Canada) or a Nox T3 device (Nox Medical, Reykjavik, Iceland) . The same signals were recorded on all studies: nasal airflow by cannula, oxygen saturation, heart rate, respiratory movements by respiratory inductance plethysmography (RIP) belts, body position and activity. Trained sleep technologists scored all sleep studies, and the studies had to have ≥4 h of a scorable O 2 saturation signal. The AHI was calculated as the mean number of apneas and hypopneas per hour of recording (excluding upright time). The oxygen desaturation index (ODI) was calculated as the number of transient drops in oxygen saturation ≥4% per hour of recording. For further details, see previous publications (Arnardottir et al., 2013a,b; Bjornsdottir et al., 2013; Bj€ ornsdottir et al., 2015) . 
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Statistical analyses
All statistical analyses were performed in STATA, version 13.0 (Stata, College Station, TX, USA). For bivariate analysis, the chi-square test and t-test were used for nominal and continuous variables, respectively. Logistic regression was used in adjusted analyses, and results are presented as adjusted b-estimates and 95% confidence intervals or adjusted least-squares mean estimates and standard errors. The data were square root transformed for statistical analysis as appropriate to normalize distributions.
RESUL TS
Among the 796 subjects in this study (males = 644, females = 152), the mean follow-up time was 6.7 AE 1.2 years. Altogether, 36.8% (n = 293) had stopped using the PAP device and 63.2% (n = 503) were still on PAP treatment. Non-adherent patients were divided into two groups: early quitters who stopped using PAP <1 year (n = 123); and late quitters who stopped on PAP after ≥1 year (n = 170; Fig. 1 ).
Different characteristics of early quitters and long-term PAP users
The characteristics of the two groups differed at baseline. Those who stopped using their PAP device in the first year after initiation had a lower BMI, milder OSA, less daytime sleepiness and reported less often nocturnal sweating, as well as a lower prevalence of hypertension, compared with long-term PAP users (Table 1) . No differences were found in age, quality of life, prevalence of CVD or diabetes, or symptoms of nasal airway restriction between the groups. Subjects with a higher BMI were more likely to stay on PAP treatment, and being an early quitter was most prevalent among subjects with BMI <30 kg m À2 . (Fig. 2) . A higher ESS score was related to increased PAP adherence, independent of OSA severity. When looking at baseline sleep-related symptoms, early quitters were more likely to suffer from initial and late insomnia as well as sleep bruxism compared with long-term PAP users (Table 2 ). However, no differences were found in the prevalence of RLS. There was no significant difference in any of the sleep-related symptoms between late quitters and long-term PAP users.
Because the above results show that the most distinctive difference between these three groups (early quitters, late quitters, and long-term PAP users) is between early quitters and long-term PAP users, late quitters were dropped from all following analyses.
Association of insomnia, RLS and sleep bruxism with being an early PAP quitter for different BMI categories
Logistic regression was performed to explore the adjusted associations of modifiable symptoms with being an early quitter for subjects in different BMI categories. The covariates that were adjusted for in the model were selected a priori, these were AHI score, ESS score, age and gender. Initial insomnia and late insomnia were significantly associated with being an early quitter among subjects with BMI <30 kg m À2 .
In more obese subjects none of these symptoms was associated with early quitting after adjustment. Among the most obese subjects (BMI >35 kg m À2 ), those with RLS or either middle or late insomnia were less likely to be early quitters (Table 3; Table S1 in supplement).
Changes in PAP adherence during the study period
The prevalence of early quitters decreased between years during the study period from 2005 to 2009. Of those who started on PAP in 2005, 24.5% were early quitters compared with 10.7% of those who started in 2009 (P = 0.001; Fig. 3 ). Those who started treatment later in the study period had a higher BMI, were somewhat sleepier, and had more severe OSA compared with subjects who started PAP treatment earlier in the period (Table S2 ). However, after adjusting for AHI, BMI, ESS score, age and gender, there was still a significant association between the year that PAP treatment was initiated and PAP adherence (P = 0.03).
DI SCUSSION
In our well-defined large cohort of adults with OSA, almost two-thirds of the subjects were long-term PAP users after an average of 7 years. These long-term users had a higher BMI, more severe OSA, more daytime sleepiness and a higher prevalence of hypertension at baseline than those who quit PAP treatment. Furthermore, subjects who stopped using PAP within 1 year of treatment initiation were more likely to report baseline symptoms of initial and late insomnia after adjusting for OSA severity and daytime sleepiness. When looking at these associations in different BMI categories, we found that symptoms of initial and late insomnia were associated with non-adherence among non-obese subjects (BMI <30 kg m À2 ) but not among obese subjects (BMI
≥30 kg m À2
). This indicates that personalized interventions aimed at improving symptoms of insomnia might potentially improve PAP adherence for non-obese patients with OSA.
The strengths of this study are the size of the cohort and the long-term follow-up. The data are nationwide as LSH is the sole provider of PAP treatment in Iceland and all patients with OSA are in a continuously updated register. The sample is clinical with various co-morbidities representing the whole spectrum of patients with OSA. Follow-up data were obtained in almost all subjects. A limitation of this study is the lack of precise PAP usage data, we knew which patients had a PAP device and paid the monthly fee, but not the hours per night the patients used the device. Given the magnitude of the fee, it seems reasonable to assume that individuals paying this are continuing to use PAP. This is, moreover, a well-defined group of 796 patients that has been followed precisely over time. The majority of these patients came in for a 2-year follow-up where their adherence was monitored objectively via PAP download for the last month of usage (Arnardottir et al., 2013a,b; Bjornsdottir et al., 2013) . At this 2-year follow-up the majority were PAP users and, according to objective data from memory cards, the average (AESD) use per night was 6.2 AE 2.0 h (Arnardottir et al., 2013a,b; Bjornsdottir et al., 2013) .
Our results regarding the overall long-term adherence to PAP treatment are similar to data reported from McArdle et al. (1999) , where the 5-year adherence to PAP was 68% among 1155 patients. Galetke et al. (2011) and Salepci et al. (2013) had similar results, but other studies have reported (Kribbs et al., 1993) and higher adherence (Bouloukaki et al., 2014; Kohler et al., 2010; Zeller et al., 2013) .
Previous studies have also shown that higher OSA severity is strongly associated with long-term PAP adherence (Galetke et al., 2011; Kohler et al., 2010; Schoch et al., 2014) . The relationship between long-term PAP adherence and obesity has been unclear; some studies find increased adherence with higher BMI (Gagnadoux et al., 2011; Kribbs et al., 1993; McArdle et al., 1999) after adjustment for OSA severity similar to our findings. In one study, the best adherence was among overweight subjects (Schoch et al., 2014) , while others have found no relationship with BMI (Galetke et al., 2011; Kohler et al., 2010) . In line with results from Schoch et al. (2014) , we also found an independent association between long-term PAP adherence and increased ESS score at baseline, but this is unlike most other studies (Galetke et al., 2011; Kohler et al., 2010; Zeller et al., 2013) , which have not found a relationship with the ESS score independent of OSA severity.
Sleep bruxism was related to early quitting in our unadjusted model but, when adjusting for BMI, OSA severity, daytime sleepiness, age and gender, sleep bruxism was no longer significant. Symptoms of RLS were not related to PAP nonadherence in our study, but the most obese subjects with RLS in our study were less likely to quit PAP during the first year of treatment. Symptoms of initial and late insomnia were related to early quitting among non-obese subjects in our study after adjusting for OSA severity, daytime sleepiness, age and gender. This is in agreement with our previous publications from the ISAC study (Bjornsdottir et al., 2013) . Evaluation of insomnia among all patients with OSA starting PAP and treating symptoms of initial and late insomnia if present could potentially increase initial PAP adherence among non-obese patients.
In our study there was an improvement in adherence during the study period (2005) (2006) (2007) (2008) (2009) , as those who started more recently on PAP were less likely to become early quitters. Possible explanations for the increased PAP adherence over the years are technical improvements in PAP equipment with less noisy machines and more comfortable masks, general use of nasal masks and nasal pillows versus full face masks as well as increased use of heated humidifiers (Sommer et al., 2014; Zeller et al., 2013) . There were no changes in patients' selection criteria for PAP treatment at the hospital during the study period. The PAP initiation process did not go through any formal changes and no interventions were introduced in an attempt to increase PAP adherence. Increased experience among the nurses providing support for PAP initiation could possibly have influenced the adherence, but no data exist regarding that factor.
In summary, almost two-thirds of patients with moderate to severe OSA are regular PAP users after an average of 7 years. Obesity, OSA severity and sleepiness are all important determinants of long-term adherence, but symptoms of initial and late insomnia are related to early quitting on PAP among non-obese subjects.
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